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Poster Session II 145tolerants was small, there was a trend for downregulation of genes
associated with T cell activation and up regulation of genes associ-
ated with apoptosis in the former. These preliminary data demon-
strate significant differences in gene transcription in CD41 T
cells in patients presumed to have achieved immunological toler-
ance compared to control CD41 T cells suggesting that tolerance
in HCT patients is not simply attributable to clonal deletion but
rather that anergy in these cases is an active process maintained
by measurable alterations in transcriptional and possibly metabolic
activity.399
EXAMINING HUMAN TCR CDR3 DIVERSITY DURING LYMPHOPENIA
Memon, S.A., Gress, R.E., Hakim, F.T. National Cancer Institute, NIH,
Bethesda, MD.
Investigations of T cell receptor (TCR) repertoire diversity have
contributed to our current understanding of the post-transplant ef-
fects on T cell populations of antigen-driven peripheral expansion
and thymic-dependent immune reconstitution. Spectratyping, the
RT-PCR based assessment of variation in the lengths of the com-
plementarity determining region 3 (CDR3) of the TCR BV fami-
lies, has been widely used to define oligoclonal, skewed and
polyclonal Gaussian-like repertoire diversity. The limited levels of
circulating T cells following transplantation have, however, limited
the use of this technique on clinically available samples.We here re-
port on a sensitive, reproducible and rapid method that reliably ob-
tains TCR BV spectratypes from 100,000 T cells. Key technical
elements include consistent standardization at 100,000 CD4 or
CD8 T cells for all assays, use of carriers such as glycogen and
tRNA to maximize recovery during RNA purification, detection
of DNA fragment length on sensitive DNA sequencing platforms
and broad evaluation of as many as 13 peak locations for assessment
of spectratype variation. We have determined that fewer than
100,000 T cells can result in increased random variation in spectra-
type, while a 10-fold or greater increase in cells does not alter the
proportional representation of peaks in a spectratype. The use of
small cell numbers in our technique permits evaluation of repertoire
diversity in limited clinical samples available during lymphopenia,
and supports the separation of samples into T subsets. CD41 and
CD81 populations were found to undergo distinct patterns of rep-
ertoire recovery following transplant; analysis of unsorted T cells
masks these distinctions. Further, we have sorted CD8 T cells
into naı¨ve, CD81 memory and CD81 activated cells, compared
T subset spectratypes with that of the total CD8 population, and
demonstrated recovery of repertoire diversity in naı¨ve and memory
CD8 populations that were obscured by persistent oligoclonal rep-
ertoires in effector populations. Finally, by analyzing divergence of
each patient BV family spectratype from a standard, generated by
averaging the proportional peak distributions in spectratypes from
normal adult donors, we have established a sensitive global diversity
assay to detect changes within patient repertoires. Utilizing these
techniques will broaden the utility and enhance the sensitivity of
analyses of TCR repertoire diversity.400
RESIDENT HUMAN MYELOID DENDRITIC CELL ACTIVATION AND LOCAL
ALLOGENEIC T CELL RESPONSES IN THE BONE MARROW OF HUMAN-
IZED NOD/SCID MICE
Hart, D.N.J.1, Vuckovic, S.1, Alison, R.M.1, Kato, M.1, Khalil, D.1,
Fadilah, S.A.W.2, Rodwell, R.3. 1MaterMedical Research Institute, Bris-
bane, Queensland, Australia; 2Faculty ofMedicine, HUKM,Kuala Lum-
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Resident human dendritic cells (DC) in vascularized lymphoid
organs such as bone marrow (BM) and spleen (SP) may contribute
significant T cell responses to the overall systemic immune re-
sponses. To address this possibility in vivo, we developed humanized
(hu)NOD/SCID mice, which contain human resident DC in the
BM and SP derived from engrafted cord blood CD341 cells.When huNOD/SCIDmice were injected with polyinosinic:polycy-
tidylic acid [poly(I:C)], activation of the resident human myeloid
(M)DC occurred concurrently, in the BM and SP, within 2–8 h of
injection. Poly(I:C) activated human MDC in the BM and SP in-
creased the proportions of CD861MDC and their production of
IL-6, IL-10 and IL-12. The presence of activated resident human
MDC, prior to human allogeneic naı¨ve T cell transplantation was
associated with subsequent donor T cell activation, proliferation
and effector cell generation in the BM and SP of recipient mice.
However, the division kinetics of donor T cells appeared to be tis-
sue-specific, with those in the BM undergoing six to eight divisions,
whereas in the SP, the majority of donor T cells that entered a first
division did not undergo subsequent division.Thus, human resident
MDC in both BM and SP undergo rapid activation in response to
systemic activator and contribute, according to their location, to
distinctly different division kinetics of the locally recruited donor
T cells. The findings in this humanized mouse model highlight
the contribution of activated resident MDC in controlling local do-
nor T cell responses and have direct application to investigations on
the contribution of conditioning and DC activation to the patho-
genesis of acute graft versus host disease following clinical alloge-
neic haematopoietic stem cell transplantation.401
Melan-A SPECIFIC UMBILICAL CORD BLOOD (UCB) T CELLS SHOW EV-
IDENCE OF CYTOLYTIC FUNCTION AND PERSISTENCE IN THE UCB PE-
DIATRIC TRANSPLANT RECIPIENT
Merindol, N.K.1, Caty, M.1, Gimmig, S.2, Duval, M.3,
Champagne, M.3, Soudeyns, H.1. 1CHU Sainte Justine, Montreal,
QC, Canada; 2CHUM Saint Luc, Montreal, QC, Canada; 3CHU
Sainte Justine, Montreal, QC, Canada.
UCB has been used successfully as a source of progenitor cells to
treat a variety of haematological and immune disorders in children.
Donor-derived T cells play a key role in antitumoral and antiviral
immunity and contribute to the survival of the graft recipient.
Here we studied the diversity, fate and antitumoral function of
UCB-derived T cells and characterized their persistence and possi-
ble role in the pediatric graft recipient. Naı¨ve CD81T cells specific
for the Melan-A26–35 peptide (ELAGIGILTV) were isolated from
UCB and UCB transplant recipients at 1, 3, and 6 months post-
transplant using Melan-A26–35-HLA-A2 tetramers and cell sorting,
and were cultured in the presence of IL-2, IL-7, PHA and/or
cognate peptide. Melan-A-specific cytotoxicity was tested in
51Cr-release assays, and the clonal diversity of the pre-immune
Melan-A-specific repertoire was determined by sequencing of the
T cell receptor (TCR) b chain CDR3 region.
On the one hand, 12 UCB units were analysed for the diversity of
their Melan-A specific pre-immune T cell repertoire. Using pep-
tide-MHC tetramers, Melan-A-specific CD81 T cells were de-
tected at a median frequency of 0.11% in 83.3% of UCB samples
tested. Following in vitro stimulation with Melan-A peptide, all
UCB samples tested (n5 12) remained Melan-A tetramer-positive,
themedian frequency of tetramer-positive cells in CD81T cells was
increased significantly (p\0.0001), T cell microcultures exhibited
Melan-A-specific cytolytic activity, and the TCR beta chain reper-
toire showed evidence of oligoclonality consistent with antigen-
driven expansion.
On the other hand, 14 UCB recipients were enrolled in our pro-
spective study group. When samples from UCB units used for UCB
transplant were examined, Melan-A-tetramer-positive T cells were
detected in CD81 T cells (median frequency of 1.0%). These cells
proliferated in the presence of Melan-A peptide (4 of 6 cases) and
showed cognate cytolytic activity (2 of 6 cases). Tetramer-positive
cells were detected in 2 UCB transplant recipients as early as 1
month post-transplant.
This study will allow us to better understand the fate of the pre-
immune T cell repertoire in UCB pediatric transplant recipients
and will inform on mechanisms involved in graft versus host disease
and the graft versus leukaemia effect.
